JLE

Sang Thrombose Vaisseaux

MENU

Cardiovascular toxicity related to anthracylines. What screening strategy in 2022? Volume 34, issue 3, May-June 2022

Figures


  • Figure 1.

Tables

Authors
Hôpital privé d’Antony, cardiologie, 25, rue de la providence, 92160 Antony, France
* Tirés à part : E. Alonso

Cardiovascular complications in cancer patients present a growing medical problem with high morbidity and premature mortality in this population.

Current prevention strategies include use of less cardiotoxic cancer treatment regimens, cardiovascular risk factor management, and initiation of cardio-protective therapy (CPT), either in all patients or guided by surveillance of cardiac function.